Royalty Pharma (RPRX) – Investment Analysts’ Weekly Ratings Updates

Several analysts have recently updated their ratings and price targets for Royalty Pharma (NASDAQ: RPRX):

• 5/15/2026 – Royalty Pharma was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 5/9/2026 – Royalty Pharma was upgraded by Wall Street Zen from “buy” to “strong-buy”.
• 5/7/2026 – Royalty Pharma had its price target raised by Citigroup Inc. from $50.00 to $66.00. They now have a “buy” rating on the stock.
• 5/7/2026 – Royalty Pharma had its price target raised by JPMorgan Chase & Co. from $50.00 to $58.00. They now have an “overweight” rating on the stock.
• 5/1/2026 – Royalty Pharma was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 4/21/2026 – Royalty Pharma had its price target raised by UBS Group AG from $51.00 to $57.00. They now have a “buy” rating on the stock.
• 4/10/2026 – Royalty Pharma had its price target raised by Morgan Stanley from $61.00 to $63.00. They now have an “overweight” rating on the stock.

Royalty Pharma Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s payout ratio is currently 63.95%.

Insider Buying and Selling at Royalty Pharma

In other news, Director Gregory Norden sold 3,045 shares of Royalty Pharma stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the transaction, the director directly owned 191,803 shares of the company’s stock, valued at $10,165,559. The trade was a 1.56% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 155,893 shares of company stock worth $7,512,360 in the last three months. 18.84% of the stock is currently owned by company insiders.

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.